Developer docs
API playgroundTry for free, no card

Search company profiles

ECS Botanics

Full company profile

uuid000srka

Namestring
ECS Botanics
Legal namestring
ECS Botanics Holdings Ltd
Company typeenum
Public
Founded yearint
2018
Descriptiontext

ECS Botanics Holdings Ltd (ASX: ECS) is a vertically integrated Australian medicinal cannabis company founded in 2018 and headquartered in northwestern Victoria, near the Murray River. The company cultivates cannabis organically in living soil under the Australian sun and manufactures pharmaceutical-grade dosage formats under PIC/S GMP certification (EU-GMP equivalent). It is the only certified organic Australian cultivator operating at this certification tier, with a product range spanning dried flower (15-30% THC, Sativa and Indica), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulation, and THC vape products. Underlying technology includes regenerative agriculture practices, terpene-preserving drying and curing processes, and PIC/S GMP-controlled post-harvest handling that treats cannabis flower as an active pharmaceutical ingredient.

ECS operates a hybrid B2B and B2C commercial model. The B2B segment supplies white-label and branded medicinal cannabis to pharmaceutical distributors and wholesalers in Australia, Germany, the UK, and New Zealand under multi-year binding offtake agreements totaling over A$60M, including a A$24M five-year MediCann Health deal, a A$10.2M three-year Entoura agreement, a A$9.9M three-year Ilios Santé GmbH contract, and a 10-year Sun Pharma toll processing arrangement. The B2C segment, launched in 2024, sells directly to patients through 540 prescribing medical practitioners and pharmacy dispensing, generating A$2.2M (46% of total revenue) in Q3 FY25. In September 2024, ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz for distribution of Original Z genetics across Australia, the UK, Germany, and New Zealand. The company divested non-core Tasmanian assets (TasCo, A$3M) and its hemp food business (A$250K) in 2024 to focus on its vertically integrated Victorian GMP operation.

Short descriptiontext

ECS Botanics is an ASX-listed Australian medicinal cannabis company that cultivates organic, sun-grown cannabis and manufactures PIC/S GMP-certified products (dried flower, capsules, pastilles, vapes) for B2B pharmaceutical partners and B2C patients across Australia, Germany, the UK, and New Zealand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMurrabit, Australia
HQ citystring
Murrabit
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medicinal cannabis, pharmaceutical-grade GMP, organic sun-grown cultivation, cannabinoid dosage forms, white-label cannabis manufacturing
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Medicinal Cannabis Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medicinal Cannabis Product Sales
TypeTransaction Fee
Description

ECS manufactures and supplies pharmaceutical-grade medicinal cannabis in multiple dosage formats including organically grown dried flower (15-30% THC with Sativa and Indica dominance), soft-gel capsules, pastilles (sugar-free and vegan), extracts, and THC vape products. Products are sold both under own brands (B2C) and as white-label B2B products.

ecs-botanics.com
2Offtake and Supply Agreements
TypeTransaction Fee
Description

ECS generates revenue through binding offtake agreements with distributors and retailers including MediCann Health ($24M/5-year deal), Entoura ($10.2M/3-year), Precision Pharmaceuticals ($1.7M), Ilios Santé GmbH Germany ($9.9M/3-year), and others. These contracts provide minimum volume commitments with potential for exceeding minimums.

ecs-botanics.com
3Licensing and Brand Royalties
TypeLicensing Royalties
Description

ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz in September 2024, positioning itself to launch iconic cannabis products globally including the Original Z genetics. Revenue generated from licensing arrangements and brand product sales.

ecs-botanics.com
4Contract Manufacturing (Tolling)
TypeProfessional Services
Description

ECS provides toll processing and manufacturing services for strategic partners, including a 10-year supply and toll processing agreement with Sun Pharma for cannabis biomass extraction. This leverages manufacturing capacity and expertise.

ecs-botanics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TerpHogz
Description

Licensed California cannabis brand featuring Original Z genetics, launched under an eight-year licensing agreement in September 2024 for Australian and international markets including Germany, UK, and New Zealand.

ecs-botanics.com
+1 more record
Core offering1 text field

ECS Botanics cultivates organic, sun-grown medicinal cannabis in northwestern Victoria, Australia and manufactures pharmaceutical-grade dosage formats (dried flower 15-30% THC, soft-gel capsules, pastilles, extracts, THC vapes) to PIC/S GMP (EU-GMP equivalent) standards. Products are supplied both as B2B white-label and bulk API to pharmaceutical distributors and through B2C direct-to-patient sales via prescribing practitioners and partner pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 78% revenue surge with 60% increase in outdoor cultivation area
+3 more records
Product overview1 text field

ECS Botanics is a vertically integrated medicinal cannabis company that cultivates organic, sun-grown cannabis in Victoria, Australia and manufactures to EU-GMP (PIC/S GMP) standards. The company operates a B2B business model providing white-label cultivation and manufacturing services while also developing its own retail product line. The product portfolio includes dried flower (15-30% THC, Sativa and Indica varieties with new Californian genetics), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulations, and THC vape products. The company has also licensed the TerpHogz California cannabis brand for distribution in Australia and international markets.

Product and service7 records
1Dried Flower
CategoryMedicinal cannabis dosage forms
Description

Organically grown, sun-cultivated dried cannabis flower for inhalation, available in both Sativa and Indica dominance with 15-30% THC content and new Californian genetics. Suitable for medical use or further processing in GMP licensed extraction facilities.

2Soft-gel Capsules
CategoryMedicinal cannabis dosage forms
Description

Pharmaceutical-standard capsules manufactured using high-quality cannabis extracts, delivering precise and consistent dosing in an oral format with predictable pharmacokinetics and 24-month stability.

3Pastilles (Gummies)
CategoryMedicinal cannabis dosage forms
Description

Pre-measured oral dosage forms designed for ease of use and patient preference, manufactured under EU-GMP quality systems in sugar-free and vegan options for consistent dosing.

4Cannabis Extracts
CategoryMedicinal cannabis dosage forms
Description

Resin extracted from ECS strains for the formulation of oils and other products. ECS works with strategic partners to formulate off-the-shelf and bespoke cannabinoid formulations.

5THC Vape Products
CategoryMedicinal cannabis dosage forms
Description

Pharmaceutical-standard vape formulations manufactured using high-quality cannabis extracts to deliver consistent, reliable inhalation experience with rapid onset and precise dosing.

6White-Label Manufacturing Services
CategoryCannabis manufacturing services
Description

B2B pharmaceutical manufacturing service providing cannabinoid products to strategic global partners in pharmaceutical-grade dosage formats including white-label products. Includes contract manufacturing (toll processing) such as the 10-year biomass extraction agreement with Sun Pharma.

7TerpHogz Licensed Cannabis Brand
CategoryLicensed cannabis consumer brand
Description

Licensed California cannabis brand featuring the Original Z genetics, launched under an eight-year licensing and marketing agreement for distribution across Australia, UK, Germany and New Zealand markets.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

ECS Botanics entered into a distribution partnership with Nimbus Health in Germany for medicinal cannabis products, supporting the company's European market expansion strategy.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-01
Description

ECS secured an eight-year licensing and marketing agreement with TerpHogz, a renowned cannabis breeding group from Mendocino County, California. The partnership includes the Original Z genetics and positions ECS to launch TerpHogz products in Australia, UK, Germany, and New Zealand.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-01
Description

Binding offtake agreement with UK-based Rokshaw for supply of medicinal cannabis dried flower over three years.

4Ilios Santé GmbH
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Binding three-year agreement for ECS to exclusively supply four medicinal cannabis strains to German licensed wholesaler with approval to import and distribute narcotics. Minimum revenue of $9.9 million over contract term.

ecs-botanics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-01
Description

$24 million five-year binding agreement to supply medicinal cannabis dried flower. Supply commenced January 2024 with over four tonnes of dried cannabis flower to be delivered. Builds on existing two-year contract.

6Entoura
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-01
Description

$10.2 million three-year supply agreement for GMP medicinal cannabis dried flower. ECS supplies minimum three strains exclusive to Entoura. Entoura develops high-quality medicinal cannabis products and supports research.

ecs-botanics.com
7Sun Pharma
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Collaborative 10-year supply and toll processing agreement for cannabis biomass extraction. Sun Pharma is an Australia-based subsidiary of Sun Pharmaceutical Industries, the fourth largest specialty generic pharmaceutical company globally.

ecs-botanics.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Three-year supply agreement with London-based pharmaceuticals distribution company for sale and export of medicinal cannabis oils in UK and Germany.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Supply deal for dried cannabis flower to Melbourne-based Releaf Group, Australia's first dedicated clinic and dispensary franchise group. Expected to generate approximately A$590,000 over 18-month term.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ASX-listed Australian medicinal cannabis cultivator and manufacturer with EU-GMP certification, supplying both Australian patients and European markets (notably Germany). Directly comparable in business model — vertical cultivation + GMP manufacturing + B2B wholesale and B2C branded products.

TypeDirect peer
Description

ASX-listed Australian medicinal cannabis company with cultivation, manufacturing, and domestic/international distribution. Closely comparable to ECS in regulatory positioning (TGA/PIC-S GMP) and Australian patient market focus, though at larger scale.

TypeDirect peer
Description

Australian medicinal cannabis company (ASX:AGH) with proprietary branded product range sold through prescribers and pharmacies domestically, plus UK/European expansion. Highly comparable B2C prescriber-channel model and Australian patient focus.

TypeDirect peer
Description

ASX-listed Australian medicinal cannabis company focused on manufacturing, distribution, and clinical research of cannabinoid medicines. Comparable vertically integrated Australian manufacturer targeting similar prescriber and pharmacy channels.

TypeEmerging player
Description

ASX-listed cannabinoid and psychedelic medicine developer, focused on clinical research and pharmaceutical-grade cannabinoid therapies. Comparable Australian cannabis player with pharmaceutical orientation rather than pure cultivation.

6MGC Pharmaceuticals
TypeDirect peer
Description

Australian-listed medicinal cannabis company with European operations and focus on pharmaceutical-grade cannabinoid medicines for UK, EU, and Australian markets. Comparable GMP manufacturing and cross-jurisdictional distribution strategy.

TypeDirect peer
Description

ASX-listed Australian medicinal cannabis distributor with branded patient products. Both an industry peer and an existing ECS offtake customer ($750K minimum contract), reflecting overlapping prescriber-channel positioning.

8Tilray Brands
TypeBroad incumbent
Description

Global cannabis major with established operations across Canada, US, Europe, and Australia. Competes with ECS in international medicinal cannabis distribution and is significantly larger, but overlaps directly in EU-GMP flower and extract supply.

TypeBroad incumbent
Description

Large Canadian cannabis producer with European GMP-certified operations serving Germany and other EU medical markets. Comparable EU-GMP positioning and Germany export ambition to ECS.

TypeBroad incumbent
Description

Global cannabis major with medical cannabis operations in Canada, Germany, and Australia (via Spectrum Therapeutics). Overlaps with ECS in Australian patient channels and EU medical cannabis supply.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ECS Botanics

Medicinal Cannabis Manufacturingecs-botanics.com

ECS Botanics is an ASX-listed Australian medicinal cannabis company that cultivates organic, sun-grown cannabis and manufactures PIC/S GMP-certified products (dried flower, capsules, pastilles, vapes) for B2B pharmaceutical partners and B2C patients across Australia, Germany, the UK, and New Zealand.

What ECS Botanics does

ECS Botanics Holdings Ltd (ASX: ECS) is a vertically integrated Australian medicinal cannabis company founded in 2018 and headquartered in northwestern Victoria, near the Murray River. The company cultivates cannabis organically in living soil under the Australian sun and manufactures pharmaceutical-grade dosage formats under PIC/S GMP certification (EU-GMP equivalent). It is the only certified organic Australian cultivator operating at this certification tier, with a product range spanning dried flower (15-30% THC, Sativa and Indica), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulation, and THC vape products. Underlying technology includes regenerative agriculture practices, terpene-preserving drying and curing processes, and PIC/S GMP-controlled post-harvest handling that treats cannabis flower as an active pharmaceutical ingredient.

ECS operates a hybrid B2B and B2C commercial model. The B2B segment supplies white-label and branded medicinal cannabis to pharmaceutical distributors and wholesalers in Australia, Germany, the UK, and New Zealand under multi-year binding offtake agreements totaling over A$60M, including a A$24M five-year MediCann Health deal, a A$10.2M three-year Entoura agreement, a A$9.9M three-year Ilios Santé GmbH contract, and a 10-year Sun Pharma toll processing arrangement. The B2C segment, launched in 2024, sells directly to patients through 540 prescribing medical practitioners and pharmacy dispensing, generating A$2.2M (46% of total revenue) in Q3 FY25. In September 2024, ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz for distribution of Original Z genetics across Australia, the UK, Germany, and New Zealand. The company divested non-core Tasmanian assets (TasCo, A$3M) and its hemp food business (A$250K) in 2024 to focus on its vertically integrated Victorian GMP operation.

ECS Botanics firmographics

Firmographics
Name
ECS Botanics
Legal name
ECS Botanics Holdings Ltd
Website
https://ecs-botanics.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
ECS Botanics is an ASX-listed Australian medicinal cannabis company that cultivates organic, sun-grown cannabis and manufactures PIC/S GMP-certified products (dried flower, capsules, pastilles, vapes) for B2B pharmaceutical partners and B2C patients across Australia, Germany, the UK, and New Zealand.
Ownership category
akta.pro rank

Where ECS Botanics is headquartered

Location

Headquarters

HQ city
Murrabit
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

ECS Botanics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Medicinal Cannabis Product Sales: ECS manufactures and supplies pharmaceutical-grade medicinal cannabis in multiple dosage formats including organically grown dried flower (15-30% THC with Sativa and Indica dominance), soft-gel capsules, pastilles (sugar-free and vegan), extracts, and THC vape products. Products are sold both under own brands (B2C) and as white-label B2B products.
  2. Offtake and Supply Agreements: ECS generates revenue through binding offtake agreements with distributors and retailers including MediCann Health ($24M/5-year deal), Entoura ($10.2M/3-year), Precision Pharmaceuticals ($1.7M), Ilios Santé GmbH Germany ($9.9M/3-year), and others. These contracts provide minimum volume commitments with potential for exceeding minimums.
  3. Licensing and Brand Royalties: ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz in September 2024, positioning itself to launch iconic cannabis products globally including the Original Z genetics. Revenue generated from licensing arrangements and brand product sales.
  4. Contract Manufacturing (Tolling): ECS provides toll processing and manufacturing services for strategic partners, including a 10-year supply and toll processing agreement with Sun Pharma for cannabis biomass extraction. This leverages manufacturing capacity and expertise.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

ECS Botanics product offering

Product offering

Core offering

ECS Botanics cultivates organic, sun-grown medicinal cannabis in northwestern Victoria, Australia and manufactures pharmaceutical-grade dosage formats (dried flower 15-30% THC, soft-gel capsules, pastilles, extracts, THC vapes) to PIC/S GMP (EU-GMP equivalent) standards. Products are supplied both as B2B white-label and bulk API to pharmaceutical distributors and through B2C direct-to-patient sales via prescribing practitioners and partner pharmacies.

Product overview

ECS Botanics is a vertically integrated medicinal cannabis company that cultivates organic, sun-grown cannabis in Victoria, Australia and manufactures to EU-GMP (PIC/S GMP) standards. The company operates a B2B business model providing white-label cultivation and manufacturing services while also developing its own retail product line. The product portfolio includes dried flower (15-30% THC, Sativa and Indica varieties with new Californian genetics), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulations, and THC vape products. The company has also licensed the TerpHogz California cannabis brand for distribution in Australia and international markets.

Differentiator

Problem solved

Functional benefit

Brands

  • TerpHogz: Licensed California cannabis brand featuring Original Z genetics, launched under an eight-year licensing agreement in September 2024 for Australian and international markets including Germany, UK, and New Zealand.
  • Murray Meds

Products and services

  • Dried Flower Organically grown, sun-cultivated dried cannabis flower for inhalation, available in both Sativa and Indica dominance with 15-30% THC content and new Californian genetics. Suitable for medical use or further processing in GMP licensed extraction facilities.
  • Soft-gel Capsules Pharmaceutical-standard capsules manufactured using high-quality cannabis extracts, delivering precise and consistent dosing in an oral format with predictable pharmacokinetics and 24-month stability.
  • Pastilles (Gummies) Pre-measured oral dosage forms designed for ease of use and patient preference, manufactured under EU-GMP quality systems in sugar-free and vegan options for consistent dosing.
  • Cannabis Extracts Resin extracted from ECS strains for the formulation of oils and other products. ECS works with strategic partners to formulate off-the-shelf and bespoke cannabinoid formulations.
  • THC Vape Products Pharmaceutical-standard vape formulations manufactured using high-quality cannabis extracts to deliver consistent, reliable inhalation experience with rapid onset and precise dosing.
  • White-Label Manufacturing Services B2B pharmaceutical manufacturing service providing cannabinoid products to strategic global partners in pharmaceutical-grade dosage formats including white-label products. Includes contract manufacturing (toll processing) such as the 10-year biomass extraction agreement with Sun Pharma.
  • TerpHogz Licensed Cannabis Brand Licensed California cannabis brand featuring the Original Z genetics, launched under an eight-year licensing and marketing agreement for distribution across Australia, UK, Germany and New Zealand markets.

Quantifiable outcome

  • 78% revenue surge with 60% increase in outdoor cultivation area
  • +3 more outcomes

Companies that use ECS Botanics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

ECS Botanics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ECS Botanics partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and major.

  • Nimbus HealthcoreChannel Partner/ Reseller/ Distributor · 11 February 2026ECS Botanics entered into a distribution partnership with Nimbus Health in Germany for medicinal cannabis products, supporting the company's European market expansion strategy.
  • TerpHogzcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2024ECS secured an eight-year licensing and marketing agreement with TerpHogz, a renowned cannabis breeding group from Mendocino County, California. The partnership includes the Original Z genetics and positions ECS to launch TerpHogz products in Australia, UK, Germany, and New Zealand.
  • RokshawmajorChannel Partner/ Reseller/ Distributor · 1 February 2024Binding offtake agreement with UK-based Rokshaw for supply of medicinal cannabis dried flower over three years.
  • Ilios Santé GmbHcoreChannel Partner/ Reseller/ Distributor · 1 January 2024Binding three-year agreement for ECS to exclusively supply four medicinal cannabis strains to German licensed wholesaler with approval to import and distribute narcotics. Minimum revenue of $9.9 million over contract term.
  • MediCann HealthcoreChannel Partner/ Reseller/ Distributor · 1 October 2023$24 million five-year binding agreement to supply medicinal cannabis dried flower. Supply commenced January 2024 with over four tonnes of dried cannabis flower to be delivered. Builds on existing two-year contract.
  • EntouracoreChannel Partner/ Reseller/ Distributor · 1 June 2023$10.2 million three-year supply agreement for GMP medicinal cannabis dried flower. ECS supplies minimum three strains exclusive to Entoura. Entoura develops high-quality medicinal cannabis products and supports research.
  • Sun PharmamajorStrategic or Co-development Partner · 1 November 2021Collaborative 10-year supply and toll processing agreement for cannabis biomass extraction. Sun Pharma is an Australia-based subsidiary of Sun Pharmaceutical Industries, the fourth largest specialty generic pharmaceutical company globally.
  • The Armour GroupmajorChannel Partner/ Reseller/ Distributor · 1 January 2021Three-year supply agreement with London-based pharmaceuticals distribution company for sale and export of medicinal cannabis oils in UK and Germany.
  • Releaf DispensariesmajorChannel Partner/ Reseller/ Distributor · 1 January 2021Supply deal for dried cannabis flower to Melbourne-based Releaf Group, Australia's first dedicated clinic and dispensary franchise group. Expected to generate approximately A$590,000 over 18-month term.

Scale indicators8 records

Recent moves8 records

Expansion highlights2 records

ECS Botanics competitors and assessment

Company assessment

Direct peers

  • Little Green Pharma: ASX-listed Australian medicinal cannabis cultivator and manufacturer with EU-GMP certification, supplying both Australian patients and European markets (notably Germany). Directly comparable in business model — vertical cultivation + GMP manufacturing + B2B wholesale and B2C branded products.
  • Cann Group: ASX-listed Australian medicinal cannabis company with cultivation, manufacturing, and domestic/international distribution. Closely comparable to ECS in regulatory positioning (TGA/PIC-S GMP) and Australian patient market focus, though at larger scale.
  • Althea Group Holdings: Australian medicinal cannabis company (ASX:AGH) with proprietary branded product range sold through prescribers and pharmacies domestically, plus UK/European expansion. Highly comparable B2C prescriber-channel model and Australian patient focus.
  • AusCann Group Holdings: ASX-listed Australian medicinal cannabis company focused on manufacturing, distribution, and clinical research of cannabinoid medicines. Comparable vertically integrated Australian manufacturer targeting similar prescriber and pharmacy channels.
  • MGC Pharmaceuticals: Australian-listed medicinal cannabis company with European operations and focus on pharmaceutical-grade cannabinoid medicines for UK, EU, and Australian markets. Comparable GMP manufacturing and cross-jurisdictional distribution strategy.
  • Cronos Australia: ASX-listed Australian medicinal cannabis distributor with branded patient products. Both an industry peer and an existing ECS offtake customer ($750K minimum contract), reflecting overlapping prescriber-channel positioning.

Emerging players

  • Incannex Healthcare: ASX-listed cannabinoid and psychedelic medicine developer, focused on clinical research and pharmaceutical-grade cannabinoid therapies. Comparable Australian cannabis player with pharmaceutical orientation rather than pure cultivation.

Broad incumbents

  • Tilray Brands: Global cannabis major with established operations across Canada, US, Europe, and Australia. Competes with ECS in international medicinal cannabis distribution and is significantly larger, but overlaps directly in EU-GMP flower and extract supply.
  • Aurora Cannabis: Large Canadian cannabis producer with European GMP-certified operations serving Germany and other EU medical markets. Comparable EU-GMP positioning and Germany export ambition to ECS.
  • Canopy Growth Corporation: Global cannabis major with medical cannabis operations in Canada, Germany, and Australia (via Spectrum Therapeutics). Overlaps with ECS in Australian patient channels and EU medical cannabis supply.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ECS Botanics social profiles

Digital presence

ECS Botanics compliance and trust

Trust signal

Compliance4 records

ECS Botanics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ECS Botanics leadership team

Management profile

Number of profiles

Profiles14 records

ECS Botanics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ECS Botanics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ECS Botanics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ECS Botanics

What does ECS Botanics do?

ECS Botanics cultivates organic, sun-grown medicinal cannabis in northwestern Victoria, Australia and manufactures pharmaceutical-grade dosage formats (dried flower 15-30% THC, soft-gel capsules, pastilles, extracts, THC vapes) to PIC/S GMP (EU-GMP equivalent) standards. Products are supplied both as B2B white-label and bulk API to pharmaceutical distributors and through B2C direct-to-patient sales via prescribing practitioners and partner pharmacies.

Is ECS Botanics a public or private company?

ECS Botanics is a public company. It is classified as public and is currently operating.

When was ECS Botanics founded?

ECS Botanics was founded in 2018. It employs 11 to 50 people.

Where is ECS Botanics based?

ECS Botanics is headquartered in Murrabit, Australia, in the Oceania region.

How does ECS Botanics make money?

Four revenue lines are on record. Medicinal Cannabis Product Sales are the primary driver. The others are offtake and Supply Agreements, licensing and Brand Royalties and contract Manufacturing (Tolling).

Who are ECS Botanics's main competitors?

Direct peers on record are Little Green Pharma, Cann Group, Althea Group Holdings, AusCann Group Holdings, MGC Pharmaceuticals and Cronos Australia. Incannex Healthcare is listed as an emerging player. Broad incumbents are Tilray Brands, Aurora Cannabis and Canopy Growth Corporation.

Does ECS Botanics have an API?

No public API is recorded for ECS Botanics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales